Wilms' tumour: treatment of 113 patients from 1960 to 1971.
The crude 5-year survival rate among children with Wilms' tumour increased from 54% for those diagnosed from 1960 to 1965 to 81% for the period 1966 to 1971. This resulted from an increased ability to cure metastatic disease and, to a lesser extent, to an increased ability to prevent relapse. It is proposed that, after resection and postoperative irradiation, maintained combination chemotherapy with actinomycin D and vincristine should be used electively to prevent relapse, but that this use should also be selective in order that overall morbidity be minimized. Of urgent priority, therefore, is improved delineation of present-day prognostic factors in children with Wilms' tumour.
D003609:Dactinomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality* / Q000628:therapy*; D008175:Lung Neoplasms / Q000401:mortality; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D009392:Nephrectomy; D011182:Postoperative Care; D011379:Prognosis; D011879:Radiotherapy Dosage; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use; D009396:Wilms Tumor / Q000401:mortality / Q000628:therapy*
D003609:Dactinomycin; D014750:Vincristine